U.S. Markets closed
  • S&P 500

    3,699.12
    +32.40 (+0.88%)
     
  • Dow 30

    30,218.26
    +248.74 (+0.83%)
     
  • Nasdaq

    12,464.23
    +87.05 (+0.70%)
     
  • Russell 2000

    1,892.45
    +43.75 (+2.37%)
     
  • Crude Oil

    46.09
    +0.45 (+0.99%)
     
  • Gold

    1,837.70
    +0.90 (+0.05%)
     
  • Silver

    24.32
    +0.18 (+0.76%)
     
  • EUR/USD

    1.2127
    -0.0022 (-0.1819%)
     
  • 10-Yr Bond

    0.9690
    +0.0490 (+5.33%)
     
  • Vix

    20.79
    -0.49 (-2.30%)
     
  • GBP/USD

    1.3438
    -0.0015 (-0.1088%)
     
  • USD/JPY

    104.1400
    +0.2800 (+0.2696%)
     
  • BTC-USD

    18,741.41
    +111.01 (+0.60%)
     
  • CMC Crypto 200

    365.19
    -14.05 (-3.71%)
     
  • FTSE 100

    6,550.23
    +59.96 (+0.92%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Seth Klarman Further Increases Translate Bio Stake

GuruFocus.com

After expanding his position in Translate Bio Inc. (NASDAQ:TBIO) at the end of August, Baupost Group leader Seth Klarman (Trades, Portfolio) disclosed on Friday that he boosted the stake another 42.96%.


The guru's Boston-based hedge fund, which manages about $24.7 billion in assets, searches for value among a broad range of opportunities, including stocks, distressed debt, liquidations and foreign securities. With a long-term horizon, the renowned investor typically seeks securities trading well below his estimate of intrinsic value and waits for their price to rise.

According to GuruFocus Real-Time Picks, a feature that is part of Premium service, Klarman invested in 5.3 million shares of Translate Bio on Sept. 18, bringing his total holding to 17.5 million shares. The stake now represents 1.63% of the equity portfolio. The stock traded for an average price of $10.01 per share.

c8bb5f54712de4ecc893f6bdd8de986a.png
c8bb5f54712de4ecc893f6bdd8de986a.png

GuruFocus data indicates the guru has lost an estimated 2.18% on the investment since establishing it in the second quarter of 2018.

The Lexington, Massachusetts-based clinical-stage biotechnology company, which focuses on developing messenger RNA therapeutics to treat diseases caused by protein or gene dysfunctions, has a $514.19 million market cap; its shares were trading around $10.08 on Monday with a price-book ratio of 3.93 and a price-sales ratio of 114.55.

After tumbling approximately 35% in 2018, GuruFocus estimates the stock has gained 36% year to date.

1749215208.png
1749215208.png

On Sept. 17, the company announced an underwritten public offering of 9 million shares, which were priced at $10 per share. In addition, underwriters were granted a 30-day option of purchasing up to an additional 1.35 million shares. The offering closed on Sept. 20.

Translate Bio's financial strength was rated 4.3 out of 10 by GuruFocus. Despite having comfortable interest coverage and a solid cash-debt ratio of 11.46, the low Altman Z-Score of -0.46 warns the company could be in danger of going bankrupt.

The company's profitability and growth fared much better, scoring a 10 out of 10 rating despite having negative margins and returns that underperform a majority of competitors.

With 34.39% of outstanding shares, Klarman is by far Transate Bio's largest guru shareholder. Jim Simons' (Trades, Portfolio) Renaissance Technologies also owns the stock.

Portfolio composition

Klarman's $10.73 billion equity portfolio, which was composed of 30 stocks as of the end of the second quarter, is largely invested in the consumer cyclical and health care sectors, followed by a smaller position in the technology space.

9614316608c148a3224554205bd19c32.png
9614316608c148a3224554205bd19c32.png

Other biotechnology stocks the guru was invested in as of the end of the second quarter were Atara Biotherapeutics Inc. (NASDAQ:ATRA), Theravance Biopharma Inc. (NASDAQ:TBPH), Akebia Therapeutics Inc. (ABKA), Gossamer Bio Inc. (NASDAQ:GOSS) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK).

Disclosure: No positions.

Read more here:

  • 3 Pharmaceutical Companies to Consider as Lawmakers Continue to Fight for Lower Drug Prices

  • 4 Real Estate Companies to Consider as Existing Home Sales Rise to 17-Month High

  • Chewy's Solid Earnings Fail to Get Investors' Tails Wagging



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.